This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
LAP degradation product reflects plasma kallikrein-dependent TGF-β activation in patients with hepatic fibrosis
SpringerPlus Open Access 01 May 2014
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Allison, M. Stromedix acquisition signals growing interest in fibrosis. Nat Biotechnol 30, 375–376 (2012). https://doi.org/10.1038/nbt0512-375
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt0512-375
This article is cited by
-
Dissecting fibrosis: therapeutic insights from the small-molecule toolbox
Nature Reviews Drug Discovery (2015)
-
LAP degradation product reflects plasma kallikrein-dependent TGF-β activation in patients with hepatic fibrosis
SpringerPlus (2014)
-
Targeting the TGFβ signalling pathway in disease
Nature Reviews Drug Discovery (2012)